Exatecan mesylate
Term · Oncology and biomedicine · MLC-T-ONC-003046
An anticancer drug that is a type of topoisomerase inhibitor. Also called DX-8951f.
A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogues.
| Identifier | MLC-T-ONC-003046 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | DX-8951f; exatecan mesylate hydrate |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-003046",
"term": "Exatecan mesylate",
"field": "Oncology and biomedicine",
"definitions": [
"An anticancer drug that is a type of topoisomerase inhibitor. Also called DX-8951f.",
"A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogues."
],
"synonyms": [
"DX-8951f",
"exatecan mesylate hydrate"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/exatecan-mesylate/"
}
Record 7,018 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.